Accuracy evaluation of contour next compared with five blood glucose monitoring systems across a wide range of blood glucose concentrations occurring in a clinical research setting.

doi:10.1089/dia.2014.0069

Paper

Accuracy evaluation of contour next compared with five blood glucose monitoring systems across a wide range of blood glucose concentrations occurring in a clinical research setting.

Published Jan 9, 2015 · L. Klaff, R. Brazg, Kristen Hughes

Diabetes technology & therapeutics

Q1 SJR score

43

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

BACKGROUND This study evaluated the accuracy of Contour(®) Next (CN; Bayer HealthCare LLC, Diabetes Care, Whippany, NJ) compared with five blood glucose monitoring systems (BGMSs) across a wide range of clinically occurring blood glucose levels. SUBJECTS AND METHODS Subjects (n=146) were ≥ 18 years and had type 1 or type 2 diabetes. Subjects' glucose levels were safely lowered or raised to provide a wide range of glucose values. Capillary blood samples were tested on six BGMSs and a YSI glucose analyzer (YSI Life Sciences, Inc., Yellow Springs, OH) as the reference. Extreme glucose values were achieved by glucose modification of the blood sample. System accuracy was assessed by mean absolute difference (MAD) and mean absolute relative difference (MARD) across several glucose ranges, with <70 mg/dL evaluated by MAD as the primary end point. RESULTS In the low glucose range (<70 mg/dL), MAD values were as follows: Accu-Chek(®) Aviva Nano (Roche Diagnostics, Indianapolis, IN), 3.34 mg/dL; CN, 2.03 mg/dL; FreeStyle Lite(®) (FSL; Abbott Diabetes Care, Inc., Alameda, CA), 2.77 mg/dL; OneTouch(®) Ultra(®) 2 (LifeScan, Inc., Milpitas, CA), 10.20 mg/dL; OneTouch(®) Verio(®) Pro (LifeScan, Inc.), 4.53 mg/dL; and Truetrack(®) (Nipro Diagnostics, Inc., Fort Lauderdale, FL), 11.08 mg/dL. The lowest MAD in the low glucose range, from CN, was statistically significantly lower than those of the other BGMSs with the exception of the FSL. CN also had a statistically significantly lower MARD than all other BGMSs in the low glucose range. In the overall glucose range (21-496 mg/dL), CN yielded the lowest MAD and MARD values, which were statistically significantly lower in comparison with the other BGMSs. CONCLUSIONS When compared with other BGMSs, CN demonstrated the lowest mean deviation from the reference value (by MAD and MARD) across multiple glucose ranges.

Observational Study

Rigorous Journal

Study Snapshot

Contour Next blood glucose monitoring system demonstrated the lowest mean deviation from reference value across multiple glucose ranges compared to other systems.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Accuracy evaluation of contour next compared with five blood glucose monitoring systems across a wide range of blood glucose concentrations occurring in a clinical research setting.

Sign up to use Study Snapshot

References

Clinical Implications and Economic Impact of Accuracy Differences among Commercially Available Blood Glucose Monitoring Systems

Accuracy differences among blood glucose monitoring systems can lead to significant clinical and economic consequences, potentially impacting patients with type 1 diabetes and type 2 diabetes.

Standards of Medical Care in Diabetes—2013

The 2013 revision of the American Diabetes Association's standards of care highlights the importance of screening, diagnostic, and therapeutic actions that improve health outcomes for diabetes patients and are cost-effective.

System Accuracy Evaluation of 43 Blood Glucose Monitoring Systems for Self-Monitoring of Blood Glucose according to DIN EN ISO 15197

The CE mark does not guarantee that all blood glucose monitoring systems provide accuracy according to the ISO standard, highlighting the need for regular standardized evaluations.

Lot-to-Lot Variability of Test Strips and Accuracy Assessment of Systems for Self-Monitoring of Blood Glucose according to ISO 15197

There is considerable lot-to-lot variability between test strip lots of the same blood glucose monitoring system, highlighting the need for manufacturers to regularly check accuracy of meters and test strips to minimize false treatment decisions.

Performance of a new blood glucose monitoring system in the hands of intended users.

The new blood glucose monitoring system in development met current accuracy guidelines and proposed tighter criteria in both capillary fingerstick and venous samples tested by people with diabetes and healthcare professionals.

Citations

Performance of a Non-Invasive System for Monitoring Blood Glucose Levels Based on Near-Infrared Spectroscopy Technology (Glucube®)

Glucube® is a promising non-invasive system for monitoring blood glucose levels, with promising capabilities supporting further research.

Testing the Real-World Accuracy of the Dexcom G6 Pro CGM during the Insulin-Only Bionic Pancreas Pivotal Trial.

The Dexcom G6 Pro CGM sensor shows real-world accuracy, improving after the first 12 hours and remaining stable after.

Walking Attenuates Postprandial Glycemic Response: What Else Can We Do without Leaving Home or the Office?

Walking is the most effective strategy for improving postprandial glycemic response, but STEP and VC_NMES can also help reduce postprandial glycemia.

Review of present method of glucose from human blood and body fluids assessment.

Current methods for assessing glucose levels in body fluids include laboratory methods, self-monitoring methods, and continuous methods, with development focused on non-invasive, continuous biosensors.

CGM readings during patient-reported symptomatic hypoglycemia: assessment of the ATTD consensus definition of CGM-recorded hypoglycemia.

CGM-recorded hypoglycemia is present in two-thirds of patient-reported events, but self-monitored blood glucose measurements detect significantly more symptomatic hypoglycemic events than Medtronic iPro 2 CGM.